A review of thymic tumours

Lung Cancer

Volumn 60, Issue 1, 2008, Pages 4-13

  Srirajaskanthan, R ^a   Toubanakis, C ^a   Dusmet, M ^b   Caplin, M E ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Peptide receptor radionucleotide therapy; Surgery; Thymic carcinoma; Thymic neuroendocrine tumours; Thymoma

Indexed keywords

ANGIOPEPTIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; IFOSFAMIDE; OCTREOTIDE; PEPTIDE RECEPTOR RADIONUCLIDE; PLATINUM DERIVATIVE; PREDNISOLONE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; UROMITEXAM;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; FOLLOW UP; GENE EXPRESSION; HUMAN; NEUROENDOCRINE SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCINTIGRAPHY; THYMOMA;

FOLLOW-UP STUDIES; HUMANS; NEUROENDOCRINE TUMORS; THYMOMA; THYMUS NEOPLASMS;

EID: 41149151636     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.01.014     Document Type: Review

References (88)

1. Nishino M., Ashiku S.K., Kocher O.N., Thurer R.L., Boiselle P.M., and Hatabu H. The thymus: a comprehensive review. Radiographics 26 March (2) (2006) 335-348
2. Miller J.F. The discovery of thymus function and of thymus-derived lymphocytes. Immunol Rev 185 July (2002) 7-14
3. Miller J.F. Events that led to the discovery of T-cell development and function-a personal recollection. Tissue Antigens 63 June (6) (2004) 509-517
4. Suster S., and Rosai J. Histology of the normal thymus. Am J Surg Pathol 14 March (3) (1990) 284-303
5. Engels E.A., and Pfeiffer R.M. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 105 July 1 (4) (2003) 546-551
6. Duwe B.V., Sterman D.H., and Musani A.I. Tumors of the mediastinum. Chest 128 October (4) (2005) 2893-2909
7. Riedel R.F., and Burfeind Jr. W.R. Thymoma: benign appearance, malignant potential. Oncologist 11 September (8) (2006) 887-894
8. Verley J.M., and Hollmann K.H. Thymoma. A comparative study of clinical stages, histologic features, and survival in 200 cases. Cancer 55 March 1 (5) (1985) 1074-1086
9. Blumberg D., Port J.L., Weksler B., Delgado R., Rosai J., Bains M.S., et al. Thymoma: a multivariate analysis of factors predicting survival. Ann Thorac Surg 60 October (4) (1995) 908-913
10. Lewis J.E., Wick M.R., Scheithauer B.W., Bernatz P.E., and Taylor W.F. Thymoma. A clinicopathologic review. Cancer 60 December 1 (11) (1987) 2727-2743
11. Wang L.S., Huang M.H., Lin T.S., Huang B.S., and Chien K.Y. Malignant thymoma. Cancer 70 July 15 (2) (1992) 443-450
12. Lopez-Cano M., Ponseti-Bosch J.M., Espin-Basany E., Sanchez-Garcia J.L., and rmengol-Carrasco M. Clinical and pathologic predictors of outcome in thymoma-associated myasthenia gravis. Ann Thorac Surg 76 November (5) (2003) 1643-1649
13. Detterbeck F.C., and Parsons A.M. Thymic tumors. Ann Thorac Surg 77 May (5) (2004) 1860-1869
14. Drachman D.B. Myasthenia gravis. N Engl J Med 330 June 23 (25) (1994) 1797-1810
15. Buckley C., Douek D., Newsom-Davis J., Vincent A., and Willcox N. Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis. Ann Neurol 50 July (1) (2001) 64-72
16. Strobel P., Helmreich M., Menioudakis G., Lewin S.R., Rudiger T., Bauer A., et al. Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas. Blood 100 July 1 (1) (2002) 159-166
17. Scarpino S., Di N.A., Stoppacciaro A., Antonelli M., Pilozzi E., Chiarle R., et al. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol 149 September (3) (2007) 504-512
18. Marx A., Muller-Hermelink H.K., and Strobel P. The role of thymomas in the development of myasthenia gravis. Ann NY Acad Sci 998 September (2003) 223-236
19. Strobel P., Rosenwald A., Beyersdorf N., Kerkau T., Elert O., Murumagi A., et al. Selective loss of regulatory T cells in thymomas. Ann Neurol 56 December (6) (2004) 901-904
20. Mangan K.F., Volkin R., and Winkelstein A. Autoreactive erythroid progenitor-T suppressor cells in the pure red cell aplasia associated with thymoma and panhypogammaglobulinemia. Am J Hematol 23 October (2) (1986) 167-173
21. Kelleher P., and Misbah S.A. What is Good's syndrome? Immunological abnormalities in patients with thymoma. J Clin Pathol 56 January (1) (2003) 12-16
22. Evoli A., Minicuci G.M., Vitaliani R., Battaglia A., Della M.G., Lauriola L., et al. Paraneoplastic diseases associated with thymoma. J Neurol 254 June (6) (2007) 756-762
23. de Beukelaar J.W., and Sillevis Smitt P.A. Managing paraneoplastic neurological disorders. Oncologist 11 March (3) (2006) 292-305
24. Buckley C., Newsom-Davis J., Willcox N., and Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?. Neurology 57 November 13 (9) (2001) 1579-1582
25. Vernino S., and Lennon V.A. Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res 10 November 1 (21) (2004) 7270-7275
26. Williams C.L., and Lennon V.A. Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, alpha actinin, or actin. J Exp Med 164 October 1 (4) (1986) 1043-1059
27. Magois E., Guigay J., Blancard P.S., Margery J., Milleron B., Lher P., et al. Multimodal treatment of thymic carcinoma: report of nine cases. Lung Cancer July 3 (2007)
28. Negron-Soto J.M., and Cascade P.N. Squamous cell carcinoma of the thymus with paraneoplastic hypercalcemia. Clin Imaging 19 April (2) (1995) 122-124
29. Suzuki K., Tanaka H., Shibusa T., Shibuya Y., Inuzuka M., Fujishima T., et al. Parathyroid-hormone-related-protein-producing thymic carcinoma presenting as a giant extrathoracic mass. Respiration 65 1 (1998) 83-85
30. Eng T.Y., Fuller C.D., Jagirdar J., Bains Y., and Thomas Jr. C.R. Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys 59 July 1 (3) (2004) 654-664
31. Rosai J., and Higa E. Mediastinal endocrine neoplasm, of probable thymic origin, related to carcinoid tumor. Clinicopathologic study of 8 cases. Cancer 29 April (4) (1972) 1061-1074
32. Chaer R., Massad M.G., Evans A., Snow N.J., and Geha A.S. Primary neuroendocrine tumors of the thymus. Ann Thorac Surg 74 November (5) (2002) 1733-1740
33. Moran C.A., and Suster S. Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases. Am J Clin Pathol 114 July (1) (2000) 100-110
34. Gal A.A., Kornstein M.J., Cohen C., Duarte I.G., Miller J.I., and Mansour K.A. Neuroendocrine tumors of the thymus: a clinicopathological and prognostic study. Ann Thorac Surg 72 October (4) (2001) 1179-1182
35. Axelson J., Kobari M., Furukawa T., and Matsuno S. Thymic carcinoid in the pancreas: metastatic disease or new primary tumours. Eur J Surg 165 March (3) (1999) 270-273
36. de P.M., Spiliopoulos A., Fischer S., Totsch M., and Keshavjee S. Neuroendocrine carcinoma (carcinoid) of the thymus associated with Cushing's syndrome. Ann Thorac Surg 73 February (2) (2002) 675-681
37. Satta J., Ahonen A., Parkkila S., Leinonen L., Paja-Sarkkinen M., Lepojarvi M., et al. Multiple endocrine neoplastic-associated thymic carcinoid tumour in close relatives: octreotide scan as a new diagnostic and follow-up modality. Two case reports. Scand Cardiovasc J 33 1 (1999) 49-53
38. Boix E., Pico A., Pinedo R., Aranda I., and Kovacs K. Ectopic growth hormone-releasing hormone secretion by thymic carcinoid tumour. Clin Endocrinol (Oxf) 57 July (1) (2002) 131-134
39. Lowenthal R.M., Gumpel J.M., Kreel L., McLaughlin J.E., and Skeggs D.B. Carcinoid tumour of the thymus with systemic manifestations: a radiological and pathological study. Thorax 29 September (5) (1974) 553-558
40. Ferolla P., Falchetti A., Filosso P., Tomassetti P., Tamburrano G., Avenia N., et al. Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series. J Clin Endocrinol Metab 90 May (5) (2005) 2603-2609
41. Gibril F., Chen Y.J., Schrump D.S., Vortmeyer A., Zhuang Z., Lubensky I.A., et al. Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 88 March (3) (2003) 1066-1081
42. Masaoka A., Monden Y., Nakahara K., and Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 48 December 1 (11) (1981) 2485-2492
43. Koga K., Matsuno Y., Noguchi M., Mukai K., Asamura H., Goya T., et al. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int 44 May (5) (1994) 359-367
44. Yamakawa Y., Masaoka A., Hashimoto T., Niwa H., Mizuno T., Fujii Y., et al. A tentative tumor-node-metastasis classification of thymoma. Cancer 68 November 1 (9) (1991) 1984-1987
45. Marx A., Strobel P., Zettl A., Chan J.K.C., Harris N.L., Shimosato Y., et al. Tumours of the thymus. In: Travis W., Brambilla E., and Harris C.C. (Eds). WHO Classification of tumours. Pathology and genetics of tumours of the lung, thymus and heart, vol 7 ed. (2004), Lyon: IARC 93-145
46. Bedini A.V., Andreani S.M., Tavecchio L., Fabbri A., Giardini R., Camerini T., et al. Proposal of a novel system for the staging of thymic epithelial tumors. Ann Thorac Surg 80 December (6) (2005) 1994-2000
47. Rosai J. World Health Organization international histological classification of tumours. 2nd ed. (1999), Springer-Verlag, Berlin
48. Suster S. Diagnosis of thymoma. J Clin Pathol 59 December (12) (2006) 1238-1244
49. Strobel P., Marx A., Zettl A., and Muller-Hermelink H.K. Thymoma and thymic carcinoma: an update of the WHO Classification 2004. Surg Today 35 10 (2005) 805-811
50. Okumura M., Ohta M., Tateyama H., Nakagawa K., Matsumura A., Maeda H., et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 94 February 1 (3) (2002) 624-632
51. Klemm K.M., and Moran C.A. Primary neuroendocrine carcinomas of the thymus. Semin Diagn Pathol 16 February (1) (1999) 32-41
52. Tomiyama N., Honda O., Tsubamoto M., Inoue A., Sumikawa H., Kuriyama K., et al. Anterior mediastinal tumors: diagnostic accuracy of CT and MRI. Eur J Radiol November 17 (2007)
53. de G.G., Webb W.R., and Gamsu G. Normal thymus: assessment with MR and CT. Radiology 158 February (2) (1986) 313-317
54. Sung Y.M., Lee K.S., Kim B.T., Choi J.Y., Shim Y.M., and Yi C.A. 18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups. J Nucl Med 47 October (10) (2006) 1628-1634
55. Leondi A., Koutsikos J., and Zerva C. Interpretation of the post-surgical somatostatin receptor scintigram of a primary neuroendocrine tumor of the thymus: a case report and literature review. Int Semin Surg Oncol 2 March 23 (1) (2005) 7
56. Maggi G., Giaccone G., Donadio M., Ciuffreda L., Dalesio O., Leria G., et al. Thymomas. A review of 169 cases, with particular reference to results of surgical treatment. Cancer 58 August 1 (3) (1986) 765-776
57. Singhal S., Shrager J.B., Rosenthal D.I., LiVolsi V.A., and Kaiser L.R. Comparison of stages I-II thymoma treated by complete resection with or without adjuvant radiation. Ann Thorac Surg 76 November (5) (2003) 1635-1641
58. Giaccone G. Treatment of malignant thymoma. Curr Opin Oncol 17 March (2) (2005) 140-146
59. Wright C.D., Fidias P., Choi N.C., Shepard J.A., and Hasserjian R.P. Case records of the Massachusetts General Hospital. Case 16-2007. A 61-year-old man with a mediastinal mass. N Engl J Med 356 May 24 (21) (2007) 2185-2193
60. Wright C.D. Management of thymomas. Crit Rev Oncol Hematol Jun 12 (2007)
61. Maggi G., Casadio C., Cavallo A., Cianci R., Molinatti M., and Ruffini E. Thymoma: results of 241 operated cases. Ann Thorac Surg 51 January (1) (1991) 152-156
62. Okumura M., Miyoshi S., Takeuchi Y., Yoon H.E., Minami M., Takeda S.I., et al. Results of surgical treatment of thymomas with special reference to the involved organs. J Thorac Cardiovasc Surg 117 March (3) (1999) 605-613
63. Kondo K., and Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 76 September (3) (2003) 878-884
64. Johnson S.B., Eng T.Y., Giaccone G., and Thomas Jr. C.R. Thymoma: update for the new millennium. Oncologist 6 3 (2001) 239-246
65. Fukai I., Masaoka A., Fujii Y., Yamakawa Y., Yokoyama T., Murase T., et al. Thymic neuroendocrine tumor (thymic carcinoid): a clinicopathologic study in 15 patients. Ann Thorac Surg 67 January (1) (1999) 208-211
66. Lucchi M., Melfi F., Dini P., Basolo F., Viti A., Givigliano F., et al. Neoadjuvant chemotherapy for stage III and IVA thymomas: a single-institution experience with a long follow-up. J Thorac Oncol 1 May (4) (2006) 308-313
67. Loehrer Sr. P.J., Chen M., Kim K., Aisner S.C., Einhorn L.H., Livingston R., et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol 15 September (9) (1997) 3093-3099
68. Kim E.S., Putnam J.B., Komaki R., Walsh G.L., Ro J.Y., Shin H.J., et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 44 June (3) (2004) 369-379
69. Bretti S., Berruti A., Loddo C., Sperone P., Casadio C., Tessa M., et al. Multimodal management of stages III-IVa malignant thymoma. Lung Cancer 44 April (1) (2004) 69-77
70. Huang J., Rizk N.P., Travis W.D., Seshan V.E., Bains M.S., Dycoco J., et al. Feasibility of multimodality therapy including extended resections in stage IVA thymoma. J Thorac Cardiovasc Surg 134 December (6) (2007) 1477-1483
71. Venuta F., Rendina E.A., Longo F., De G.T., Anile M., Mercadante E., et al. Long-term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg 76 December (6) (2003) 1866-1872
72. Monden Y., Nakahara K., Iioka S., Nanjo S., Ohno K., Fujii Y., et al. Recurrence of thymoma: clinicopathological features, therapy, and prognosis. Ann Thorac Surg 39 February (2) (1985) 165-169
73. Regnard J.F., Magdeleinat P., Dromer C., Dulmet E., de M V., Levi J.F., et al. Prognostic factors and long-term results after thymoma resection: a series of 307 patients. J Thorac Cardiovasc Surg 112 August (2) (1996) 84-376
74. Ruffini E., Mancuso M., Oliaro A., Casadio C., Cavallo A., Cianci R., et al. Recurrence of thymoma: analysis of clinicopathologic features, treatment, and outcome. J Thorac Cardiovasc Surg 113 January (1) (1997) 55-63
75. Chahinian A.P. Chemotherapy of thymomas and thymic carcinomas. Chest Surg Clin N Am 11 May (2) (2001) 447-456
76. Cowen D., Richaud P., Mornex F., Bachelot T., Jung G.M., Mirabel X., et al. Thymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature. FNCLCC trialists. Federation Nationale des Centres de Lutte Contre le Cancer. Radiother Oncol 34 January (1) (1995) 9-16
77. Daniele O., and Fornasiero A. Ifosfamide in thymic neoplasms. Oncology 65 Suppl 2 (2003) 44-45
78. Hanna N., Gharpure V.S., Abonour R., Cornetta K., and Loehrer Sr. P.J. High-dose carboplatin with etoposide in patients with recurrent thymoma: the Indiana University experience. Bone Marrow Transpl 28 September (5) (2001) 435-438
79. Kvols L.K. Therapy of the malignant carcinoid syndrome. Endocrinol Metab Clin North Am 18 June (2) (1989) 557-568
80. Loehrer Sr. P.J., Wang W., Johnson D.H., Aisner S.C., and Ettinger D.S. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 22 January 15 (2) (2004) 293-299
81. Oberg K., Kvols L., Caplin M., Delle F.G., de H.W., Rindi G., et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15 June (6) (2004) 966-973
82. Dosios T., Nikou G.C., Toubanakis C., Filippides T., and Papachristou D. Multimodality treatment of neuroendocrine tumors of the thymus. Thorac Cardiovasc Surg 53 October (5) (2005) 305-309
83. McStay M.K., and Caplin M.E. GI hormone producing tumours: syndromes and treatment options. In: Johnson C.D., and Imrie C.W. (Eds). Pancreatic disease: basic science and clinical management (2003), Springer, London 31-53
84. van E.M., Krenning E.P., Bakker W.H., de Herder W.W., van Aken M.O., and Kwekkeboom D.J. Peptide receptor radionuclide therapy with (177) Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging January 27 (2007)
85. Kurup A., Burns M., Pao W., and Loeherer P.J. Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol 23 Part 1 (2005) 7068 [Ref. type: Abstract]
86. Strobel P., Hartmann M., Jakob A., Mikesch K., Brink I., Dirnhofer S., et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 350 June 17 (25) (2004) 2625-2626
87. Farina G., Garassino M.C., Gambacorta M., La V.N., Gherardi G., and Scanni A. Response of thymoma to cetuximab. Lancet Oncol 8 May (5) (2007) 449-450
88. Chuah C., Lim T.H., Lim A.S., Tien S.L., Lim C.H., Soong R., et al. Dasatinib induces a response in malignant thymoma. J Clin Oncol 24 December 1 (34) (2006) e56-e58